Publication Name	World Journal of Gastroenterology
Manuscript ID	6398
Country	United States

Received	2013-10-16 12:48
Peer-Review Started	2013-10-17 18:30
To Make the First Decision	2013-12-03 18:58
Return for Revision	2013-12-05 11:02
Revised	2013-12-13 08:58
Second Decision	2014-01-05 14:57
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-01-05 15:19
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-02-24 16:08
Publish the Manuscript Online	2014-03-06 14:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Topic Highlights
Article Title	Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options?
Manuscript Source	Invited Manuscript
All Author List	Evan J Walker and Andrew H Ko
Funding Agency and Grant Number
Corresponding Author	Andrew H Ko, MD, Associate Professor of Medicine, University of California, Helen Diller Family Comprehensive Cancer Center, 1600 Divisadero St, Box 1705, San Francisco, CA 94115, United States. andrewko@medicine.ucsf.edu
Key Words	Pancreatic cancer; Refractory; Second-line chemotherapy; Gemcitabine
Core Tip	No standard of care exists for patients with advanced pancreatic cancer who have progressed on front-line chemotherapy. To date, most available evidence has come from small non-randomized studies, with efficacy results that have been fairly dismal. In this review, we discuss both traditional and novel cytotoxic and targeted therapies that have been evaluated in this refractory setting and how they may (or may not) be applicable to clinical practice; and raise considerations for clinical trial design in the future, particularly in this current era of both expanding chemotherapeutic options and molecular/“precision” medicine.
Publish Date	2014-03-06 14:13
Citation	Walker EJ, Ko AH. Beyond first-line chemotherapy for advanced pancreatic cancer: An expanding array of therapeutic options? World J Gastroenterol 2014; 20(9): 2224-2236
URL	http://www.wjgnet.com/1007-9327/full/v20/i9/2224.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i9.2224

Full Article (PDF)	WJG-20-2224.pdf
Full Article (Word)	WJG-20-2224.doc
Manuscript File	6398-Review.docx
Answering Reviewers	6398-Answering reviewers.pdf
Copyright License Agreement	6398-Copyright assignment.pdf
Peer-review Report	6398-Peer review(s).pdf
Scientific Editor Work List	6398-Scientific editor work list.doc